Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2015

Study Completion Date

May 31, 2016

Conditions
Phenylketonuria
Interventions
OTHER

GMP Diet/GMP Medical Foods

The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.

OTHER

AA Diet/AA Medical Foods

The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.

Trial Locations (2)

53706

University of Wisconsin-Madison, Madison

02115

Children's Hospital of Boston, Boston

All Listed Sponsors
collaborator

Boston Children's Hospital

OTHER

lead

University of Wisconsin, Madison

OTHER

NCT01428258 - Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria | Biotech Hunter | Biotech Hunter